首页> 美国卫生研究院文献>BMC Medicine >Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

【2h】

Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

机译：72个符合Gavi资格的国家/地区的5岁以下儿童呼吸道合胞病毒（RSV）疾病的健康和经济负担以及针对RSV的潜在干预措施的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Model structure

机译：模型结构

著录项

期刊名称 BMC Medicine
作者
Xiao Li; Lander Willem; Marina Antillon; Joke Bilcke; Mark Jit; Philippe Beutels;
展开▼
作者单位

展开▼
年(卷),期 2020(18),-1
年度 2020
页码 -1
总页数 16
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Respiratory syncytial virus; Cost-effectiveness analysis; Maternal vaccination; Monoclonal antibody; Disease burden; Expected Value of Partially Perfect Information; Probabilistic sensitivity analysis; Low-income countries and lower-middle-income countries;

机译：呼吸道合胞病毒;成本效益分析;母亲疫苗接种;单克隆抗体;疾病负担;部分完全信息的预期价值;概率敏感性分析;低收入国家和中低收入国家;

相似文献

外文文献
中文文献
专利

1. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5?years in 72 Gavi-eligible countries [J] . Xiao Li, Lander Willem, Marina Antillon, BMC Medicine . 2020,第1期

机译：呼吸道合胞病毒（RSV）疾病的健康和经济负担以及5岁以下儿童免受潜在干预措施的成本效益？在72个Gavi符合条件的国家/地区
2. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007‐2012 [J] . Reeves Rachel Melanie, Hardelid Pia, Gilbert Ruth, Influenza and other respiratory viruses. . 2017,第2期

机译：估计2007年至2012年英格兰五岁以下儿童呼吸道合胞病毒（RSV）对呼吸道医院收治的负担
3. AGE-SPECIFIC ECONOMIC BURDEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) HOSPITALIZATIONS IN THE UNITED STATES, 2009-2013: AN ANALYSIS OF HEALTHCARE COST AND UTILIZATION PROJECT (HCUP) NATIONWIDE INPATIENT SAMPLE (NIS) [J] . Shah A., Narayanan S. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：美国呼吸道同性恋病毒（RSV）住院的年龄特异性经济负担，2009 - 2013年：全国保健成本和利用项目（HCUP）的分析（NIS）
4. PPARgamma- and Toll-Like Receptor-2 Agonists Might Have Therapeutical Value in Respiratory Syncytial Virus (RSV)-Induced Airway Diseases PPARgamma Agonists May Act in a PPARgamma-Independent Manner [C] . R. Arnold, W. Konig Collegium Internationale Allergologicum . 2007

机译：pParγ-和Toll样受体-2激动剂可能对呼吸道合胞病毒（RSV）的治疗值（RSV）诱导的气道疾病Pparγ激动剂可以以ppargamma独立的方式行事
5. Pediatric Disease Burden Attributable to Respiratory Syncytial Virus (RSV): an application of temporal models and a modified birth-cohort analysis. [D] . Lloyd, Patricia Calderon. 2014

机译：呼吸道合胞病毒（RSV）引起的小儿疾病负担：时态模型的应用和改良的出生队列分析。
6. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model [O] . Ranju Baral, Deborah Higgins, Katie Regan, 2021

机译：利用静态队列模型在131名低收入和中等收入国家对婴儿呼吸道合胞病毒（RSV）的影响和成本效益
7. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area [O] . Deshpande, S, Northern, V 2003

机译：在指定地理区域内2岁以下儿童呼吸道合胞病毒疾病的临床和健康经济负担

Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

摘要

著录项

相似文献

相关主题

期刊订阅